Search

Your search keyword '"Nishimura, Takanori"' showing total 4 results
Start Over Author "Nishimura, Takanori" Language undetermined
4 results on '"Nishimura, Takanori"'

1. Is willingness to pay (WTP) for beef quality grades affected by consumer demographics and meat consumption preferences?

Author

Lyford, Conrad P., Thompson, John M., Polkinghorne, Rod, Miller, Mark F., Nishimura, Takanori, Neath, Kate, Allen, Paul, and Belasco, Eric J.

Subjects
beef marketing, willingness to pay, Japanese beef consumers, USA beef consumers, Irish beef consumers, Agribusiness, Agricultural and Food Policy, Agricultural Finance, Community/Rural/Urban Development, Consumer/Household Economics, Demand and Price Analysis, Environmental Economics and Policy, Financial Economics, Food Consumption/Nutrition/Food Safety, Institutional and Behavioral Economics, Livestock Production/Industries, Productivity Analysis, Research Methods/ Statistical Methods, ISSN 1442-6951
Published
2010

2. Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart

Author

Park, Min, Nishimura, Takanori, Baeza-Garza, Carlos D, Caldwell, Stuart T, Pun, Pamela Boon Li, Prag, Hiran A, Young, Tim, Sauchanka, Olga, Logan, Angela, Forkink, Marleen, Gruszczyk, Anja V, Prime, Tracy A, Arndt, Sabine, Naudi, Alba, Pamplona, Reinald, Coughlan, Melinda T, Tate, Mitchel, Ritchie, Rebecca H, Caicci, Federico, Kaludercic, Nina, Di Lisa, Fabio, Smith, Robin AJ, Hartley, Richard C, Murphy, Michael P, and Krieg, Thomas

Subjects
Glycation End Products, Advanced, Heart Failure, Male, Diabetic Cardiomyopathies, Advanced glycation endproducts (AGE), Diabetes, Heart failure with preserved ejection fraction (HFpEF), Cardiovascular Agents, Stroke Volume, Mice, Mutant Strains, Mitochondria, Heart, Ventricular Function, Left, 3. Good health, Mitochondria, Mice, Inbred C57BL, Disease Models, Animal, Ventricular Dysfunction, Left, Benzamides, Animals, Akita mice
Abstract

PURPOSE: HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. METHODS AND RESULTS: A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group. CONCLUSION: Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.

3. Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart

Author

Park, Min, Nishimura, Takanori, Baeza-Garza, Carlos D., Caldwell, Stuart T., Pun, Pamela Boon Li, Prag, Hiran A., Young, Tim, Sauchanka, Olga, Logan, Angela, Forkink, Marleen, Gruszczyk, Anja V., Prime, Tracy A., Arndt, Sabine, Naudi, Alba, Pamplona, Reinald, Coughlan, Melinda T., Tate, Mitchel, Ritchie, Rebecca H., Caicci, Federico, Kaludercic, Nina, Di Lisa, Fabio, Smith, Robin A. J., Hartley, Richard C., Murphy, Michael P., and Krieg, Thomas

Subjects
Diabetes, Advanced glycation endproducts (AGE), Heart failure with preserved ejection fraction (HFpEF), Original Article, Akita mice, 3. Good health, Mitochondria
Abstract

Purpose: HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. Methods and Results: A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group. Conclusion: Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.

4. Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart

Author

Park, Min, Nishimura, Takanori, Baeza-Garza, Carlos D., Caldwell, Stuart T., Pun, Pamela Boon Li, Prag, Hiran A., Young, Tim, Sauchanka, Olga, Logan, Angela, Forkink, Marleen, Gruszczyk, Anja V., Prime, Tracy A., Arndt, Sabine, Naudi, Alba, Pamplona, Reinald, Coughlan, Melinda T., Tate, Mitchel, Ritchie, Rebecca H., Caicci, Federico, Kaludercic, Nina, Di Lisa, Fabio, Smith, Robin A. J., Hartley, Richard C., Murphy, Michael P., and Krieg, Thomas

Subjects
Diabetes, Advanced glycation endproducts (AGE), Heart failure with preserved ejection fraction (HFpEF), Original Article, Akita mice, 3. Good health, Mitochondria
Abstract

Purpose: HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. Methods and Results: A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group. Conclusion: Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.

Catalog

Books, media, physical & digital resources
See catalog results